Contrary to some other opinions, I think she saw different routes, and went with the most practical route hoping that they'd be able to address the issue in that direction, I am sure she was always aware of Flaskworks as a potential vendor and partner for doing the scale up when they needed it, but then the opportunity arose to buy it outright and at a price the company could afford, and the development of other companies in dendritic cell therapeutics did not develop, so that was a win-win for the two companies. I think once that became an option, the Cognate route was less useful. Still useful, but this opened up the opportunity to fully own and scale the means of production with a fleshed out, fully industrializable technology that can completely revolutionize this manufacturing task. The lab machines that Flaskworks makes are clearly not the end, they are the start.
I think she shows flexibility in her dealing and strategy making, which is what you absolutely need in a CEO.
Market Data 
Markets 
AI
